Mark Stejbach Acquires 775 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) Director Mark Stejbach acquired 775 shares of the stock in a transaction dated Monday, January 5th. The shares were acquired at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 16,847 shares in the company, valued at approximately $596,215.33. This represents a 4.82% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Indivior Stock Performance

Shares of NASDAQ INDV opened at $35.51 on Friday. The stock’s 50-day simple moving average is $34.04 and its 200-day simple moving average is $25.73. The firm has a market capitalization of $4.44 billion, a PE ratio of 38.60 and a beta of 0.75. Indivior PLC has a fifty-two week low of $7.62 and a fifty-two week high of $38.00.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.72 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.38 by $0.34. The firm had revenue of $314.00 million during the quarter, compared to the consensus estimate of $257.66 million. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%. On average, sell-side analysts forecast that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Indivior News Roundup

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Management issued full‑year 2026 guidance calling for total net revenue of $1,125M–$1,195M, SUBLOCADE net revenue of $905M–$945M, non‑GAAP operating expenses of $430M–$450M, and adjusted EBITDA of $535M–$575M — guidance implies strong cash generation and SUBLOCADE remains the primary growth driver. Guidance Release
• Positive Sentiment: Multiple insiders (directors David Wheadon, Mark Stejbach, Daniel Ninivaggi, Keith Humphreys and Barbara Ryan) bought shares around ~$35.39 each in early January — combined insider purchases total roughly 4,800–4,900 shares, signaling board‑level conviction. Insider Trades Alert
• Positive Sentiment: Market commentators note INDV is trading near its 52‑week high with room to run, reflecting momentum in the stock and reinforcing positive investor sentiment. Zacks: Near 52‑Week High
• Neutral Sentiment: Wall Street coverage remains constructive (multiple Buy/Strong Buy ratings and raised targets from firms such as Piper Sandler, HC Wainwright); consensus target levels vary and may already be partially reflected in the current price. MarketBeat Analyst Summary
• Negative Sentiment: Despite the positive guidance and insider buying, the stock is trading lower intraday — higher volume suggests some profit‑taking or short‑term repositioning after recent gains. Intraday Trading Note

Hedge Funds Weigh In On Indivior

A number of hedge funds and other institutional investors have recently made changes to their positions in INDV. Oaktree Capital Management LP increased its position in Indivior by 2,241.6% in the 3rd quarter. Oaktree Capital Management LP now owns 257,785,398 shares of the company’s stock valued at $6,215,206,000 after acquiring an additional 246,776,273 shares during the period. Divisadero Street Capital Management LP grew its stake in shares of Indivior by 2,372.5% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,362,605 shares of the company’s stock valued at $81,072,000 after purchasing an additional 3,226,605 shares during the last quarter. Goldentree Asset Management LP acquired a new position in shares of Indivior in the third quarter valued at approximately $42,630,000. Newtyn Management LLC raised its stake in shares of Indivior by 61.1% during the third quarter. Newtyn Management LLC now owns 4,200,000 shares of the company’s stock worth $101,262,000 after purchasing an additional 1,592,982 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Indivior by 1,122.6% during the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock worth $23,244,000 after purchasing an additional 1,447,939 shares during the last quarter. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on INDV. Piper Sandler reissued an “overweight” rating and issued a $41.00 price target (up from $27.00) on shares of Indivior in a research report on Friday, October 31st. HC Wainwright lifted their target price on Indivior from $28.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Northland Securities set a $40.00 target price on Indivior in a report on Friday, October 31st. Zacks Research upgraded Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Indivior in a research report on Friday, October 31st. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $32.71.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.